- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04158258
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
February 12, 2024 updated by: Hoffmann-La Roche
A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
2907
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, 1426
- Instituto Alexander Fleming
-
Cordoba, Argentina, X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
Cordoba, Argentina, 5000
- Instituto Oncologico De Cordoba; Oncology
-
Moron, Argentina
- Hospital de Morón
-
Rosario, Argentina, S2000KZE
- Instituto De Oncologia De Rosario
-
Rosario, Argentina, S2000ORE
- Sanatorio de la Mujer
-
-
-
-
CE
-
Fortaleza, CE, Brazil, 60336-232
- Crio - Centro Regional Integrado de Oncologia
-
-
PR
-
Londrina, PR, Brazil, 86015-520
- Hospital do Cancer de Londrina
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 20560-120
- Instituto Nacional de Cancer - INCa; Oncologia
-
Volta Redonda, RJ, Brazil, 27251-260
- Hospital Jardim Amália
-
-
RS
-
Caxias do Sul, RS, Brazil, 95020-450
- Inst. de Vita
-
Porto Alegre, RS, Brazil, 90840-440
- Centro de Pesquisa em Oncologia
-
-
SP
-
São Paulo, SP, Brazil, 03102-002
- Instituto Brasileiro De Controle Do Câncer - IBCC; Laboratório De Patologia
-
-
-
-
-
Santiago, Chile, 8380000
- Instituto Nacional del Cancer
-
Santiago, Chile, 7591046
- Clinica Las Condes
-
Temuco, Chile, 4781151
- Hospital Dr. Hernan Henriquez Aravena
-
-
-
-
-
Barranquilla, Colombia
- Organización Clínica Bonnadona Prevenir S.A.S
-
Bogota, Colombia, 111511
- Inst. Nacional de Cancerologia; Clinica de Seno
-
Cali, Colombia
- Centro Medico Imbanaco
-
Floridablanca, Colombia
- Fundacion Cardiovascular de Colombia - Instituto del Corazón
-
-
-
-
-
La Habana, Cuba, 10300
- Hospital Hermanos Ameijeiras
-
-
-
-
-
Santo Domingo, Dominican Republic
- Instituto de Oncologia Dr. Heriberto Pieter
-
-
-
-
-
Guatemala City, Guatemala, 01015
- Grupo Angeles
-
-
-
-
-
Toluca, Mexico, 50180
- Centro Oncologico Estatal ISSEMYM
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexico, 14080
- Instituto Nacional de Cancerologia
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexico, 66278
- Hospital Zambrano Hellion TecSalud
-
-
-
-
-
Lima, Peru, Lima 41
- Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
-
Lima, Peru, Lima 34
- Instituto Nacional de Enfermedades Neoplasicas
-
Lima, Peru
- Aliada Centro Oncologico
-
-
-
-
-
Montevideo, Uruguay
- Sanatorio CASMU; Oncología
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
The patients will be recruited from approximately 10 countries and from a variety of healthcare sites (ex: specialty care, private practice, teaching institution, etc.)
Description
Inclusion Criteria:
- Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time
Exclusion Criteria:
- Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
- Patients not receiving the Roche studied medicinal product, but a biosimilar
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Bevacizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Names:
|
Trastuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Names:
|
Ado-trastuzumab emtamsine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Names:
|
Pertuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Names:
|
Atezolizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Names:
|
Capecitabine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Different Breast Cancer Subtypes at Diagnosis in Latin America
Time Frame: Baseline up to 12 months
|
Baseline up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Pathological Complete Response (pCR defined ypT0/is, N0)
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Locoregional Recurrence (LRR)
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Event Free Survival (EFS)
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Invasive Disease-Free Survival (iDFS)
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Overall Survival
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Objective Response Rate (ORR)
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Anti-Cancer Treatment Modifications
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Breast Cancer Treatment based on Different Socio-Demographics Characteristics
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants (During Observation Period) with Pregnancy
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants (during Observation Period) with Pregnancy Outcomes
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Non-Serious Adverse Events of Special Interests
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with AEs Leading to Discontinuation or Dose Modification
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants with Cardiac Safety Events
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Participants Adherent to Predefined Clinical Guideliens Regarding Anti-Cancer Treatment Regimens
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Percentage of Partcipants with Access to Biomarker Testing and Diagnostic Methods
Time Frame: Baseline up to approximately 6 years
|
Baseline up to approximately 6 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 21, 2020
Primary Completion (Estimated)
November 28, 2025
Study Completion (Estimated)
November 28, 2025
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
November 6, 2019
First Posted (Actual)
November 8, 2019
Study Record Updates
Last Update Posted (Estimated)
February 13, 2024
Last Update Submitted That Met QC Criteria
February 12, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Immune Checkpoint Inhibitors
- Trastuzumab
- Capecitabine
- Bevacizumab
- Atezolizumab
- Pertuzumab
Other Study ID Numbers
- MO39485
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States